Many group-randomised cancer trials have statistical flaws
Most group-randomised trials for the prevention and control of cancer use questionable statistical methods, suggests a review of studies published between 2002 and 2006.
Read MoreAuthor: Michael Day
More good news for Novartis’ blood pressure pill Tekturna
More potential good news has emerged for Novartis’ novel blood pressure pill Tekturna.
Read MoreSuccess in Asia for crackdown on counterfeit malaria pills
Experts working with Interpol and the Chinese authorities have struck a major blow against south-east Asia’s life-threatening trade in fake malaria tablets.
Read MorePharma marketing eyeing up nurses, report finds
The pharmaceutical industry is increasingly using its marketing operation to influence nurse-prescribers, and is being aided and abetted in this by the nursing press, it is claimed this week.
Read MoreAZ teams up with top centre for cancer pain
AstraZeneca is teaming up with one of the world’s top cancer treatment centres to develop new breakthroughs against cancer pain. The company said it would work with the University of Texas M D Anderson Cancer Center to advance understanding of neuropathic pain caused by cancer chemotherapy – a side effect that often prevents the use of optimal therapeutic dosing.
Read More- NICE backs daratumumab quadruplet for newly diagnosed transplant‑ineligible myeloma
- Anocca doses first patients with precision TCR‑T therapy
- Connecta launches phase 2a trial of neuroplasticity modulator
- Aquipta recommended by NICE for acute migraine treatment
- Talvey accepted for use in Scotland for relapsed and refractory multiple myeloma
